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Summary
Uncertainty exists regarding the relation of body size and weight change with demen-
tia risk. As populations continue to age and the global obesity epidemic shows no sign
of waning, reliable quantification of such associations is important. We examined the
relationship of body mass index, waist circumference, and annual percent weight
change with risk of dementia and its subtypes by pooling data from 19 prospective
cohort studies and four clinical trials using meta-analysis. Compared with body mass
index–defined lower-normal weight (18.5-22.4 kg/m2), the risk of all-cause dementia
was higher among underweight individuals but lower among those with upper-normal
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(22.5-24.9 kg/m2) levels. Obesity was associated with higher risk in vascular demen-
tia. Similarly, relative to the lowest fifth of waist circumference, those in the highest
fifth had nonsignificant higher vascular dementia risk. Weight loss was associated
with higher all-cause dementia risk relative to weight maintenance. Weight gain was
weakly associated with higher vascular dementia risk. The relationship between body
size, weight change, and dementia is complex and exhibits non-linear associations
depending on dementia subtype under scrutiny. Weight loss was associated with an
elevated risk most likely due to reverse causality and/or pathophysiological changes
in the brain, although the latter remains speculative.
1 | INTRODUCTION
Dementia, a disease primarily of aging, affects an estimated 47 mil-
lion people globally.1 It is a heterogeneous condition chiefly com-
prising Alzheimer disease (60-70% of cases) and vascular dementia
accounting for about 15% of cases, although the two subtypes fre-
quently co-occur.1,2 Aging, family history, and sarcopenia are
important risk factors for dementia, and there is growing evidence
that vascular risk factors, such as diabetes, may also confer
increased risk, particularly for vascular dementia, although findings
are inconsistent.3,4
Excess body weight, typically defined as having a high body mass
index (BMI), has been causally linked to a large number of chronic
conditions, particularly vascular disease.5 While the relationship
between BMI and dementia has been the subject of several large-
scale epidemiological studies, the findings have been inconsistent:
some studies have reported that only individuals at the extreme ends
of the body size spectrum (ie, underweight and obese) experience an
increased dementia risk,6,7 while others have documented positive8
and even inverse9 associations. Measures of central obesity, such as
waist circumference (WC), have been argued to be more informative
measures of obesity-related risk compared with BMI. Currently, little
is known about the association between central obesity and
dementia risk.
As nonvascular and vascular dementia have different pathophysi-
ologies, any association with body size may similarly differ according
to endpoint. Distinguishing between possible dementia subtypes in
any analysis with measures of body size may, therefore, prove infor-
mative in explaining some of the observed heterogeneity. Further,
whether sex differences exist, or if the association between body size
and dementia risk differs in middle and later life remains unclear.10,11
In this meta-analysis, we examined the relationships of body size
with all-cause dementia and possible vascular and nonvascular
dementia by sex and baseline age in participants free of dementia
who had their body size assessed at baseline and were later followed
up on dementia status. Using repeat measures, where available, we
explored the association between standardized annual weight change
during follow-up with subsequent dementia risk.
2 | METHODS
The investigators of studies that were either identified from previous
systematic reviews and meta-analyses,6,7,12-14 or who were known to
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Dementia Pooling Project15 collaborators, were contacted and asked
to contribute results for their studies (Figure S1). Seven of the 14
studies from the Dementia Pooling Project contributed data that were
included in the analyses. Additional relevant data from 28 studies
were identified from five previous systematic reviews and meta-ana-
lyses of the association. Fourteen studies that had not contributed to
previous overviews were identified through a PUBMED search by
one investigator (CMYL). This was limited to human subjects and the
period up to 1 September 2017, based on the search strategy: ([body
mass index OR body weight OR obesity OR waist circumference]
AND dementia) OR (clinical trial AND incident dementia). Studies
were deemed eligible for inclusion if BMI or WC were collected at
baseline and dementia status was available at follow-up. Subse-
quently, 42 invitations were issued inviting study investigators to col-
laborate in this pooling study. Of these, 10 studies contributed
results. Collaborators provided information on a further eight studies
that had not been identified by the literature search, or which had not
been included in previous overviews, as the data were unpublished;
six of these studies provided data. A total of 23 studies responded (n
= 2 790 753).
BMI was calculated as weight in kilogrammes divided by height in
metres squared. Directly measured (n = 2 760 602; 98.9%) and self-
report (n = 30 151; 1.1%) height and weight were used in the calcula-
tion. WC was measured either at the midpoint between rib and iliac
crest (n = 217 051; 29.9%), narrowest waist (n = 9768; 1.7%), umbili-
cus (n = 12 428; 1.3%), or narrowest waist or umbilicus (n = 486 275;
67.0%). Annual percent weight change was calculated as follows:
Five BMI categories were distinguished: underweight: less than
18.5 kg/m2; lower-normal weight: 18.5-22.4 kg/m2; upper-normal
weight: 22.5-24.9 kg/m2; overweight: 25.0-29.9 kg/m2; and obese:
greater than or equal to 30.0 kg/m2.
Dementia endpoints were defined by investigators of each indi-
vidual study. Ascertainment of dementia was by medical examination
in 12 studies (Table 1). These studies classified dementia based solely
on the Diagnostic and Statistical Manual of Method Disorders
criteria38,39 or in combination with the National Institute of Neurolog-
ical and Communication Disorders and Stroke and the Alzheimer's
Disease and Related Disorders Association criteria for Alzheimer dis-
ease40 and the National Institute of Neurological Disorders and Stroke
and the Association Internationale pour la Recherche et
l'Enseignement en Neurosciences criteria for vascular dementia.41
Other methods used in dementia ascertainment included health
records (two studies), death records (five studies), and death and
health or hospitalization records (four studies). Ten of these studies
that used other methods to ascertain dementia classified the disorder
based on the International Classification of Diseases and one study
used Read Codes42 to classify dementia (Table 1).
2.1 | Data analysis
Sex-specific hazard ratios (HRs) and 95% confidence intervals (CIs)
were obtained for all-cause dementia in relation to (a) each of five
BMI categories, with lower-normal weight as the referent group; (b)
each fifth of WC, with the first fifth as the referent group; and (c) each
of three annual percent weight change categories (greater than or
equal to 0.5% annual weight loss, less than 0.5% annual weight
change, and greater than or equal to 0.5% annual weight gain), with
less than 05% annual weight change as the referent group. Following
a pre-specified common analytic protocol, effect estimates were
adjusted for age (model 1); age, smoking, and education or socio-eco-
nomic status (model 2; which was the primary model—used in the
reporting of outcomes herein); and age, smoking, education or socio-
economic status, diabetes, systolic blood pressure, total cholesterol,
blood pressure–lowering medication, cholesterol-lowering medication,
and glucose-lowering medication where available (model 3). For stud-
ies with information on possible dementia subtype, study-specific
estimates were requested for possible vascular dementia and possible
nonvascular dementia.
A random effects meta-analysis was used to combine study-spe-
cific log HR to obtain an overall summary estimate and associated
95% CIs for BMI and WC in relation to all dementia endpoints investi-
gated. Analyses were conducted for women and men combined and
then separately. Heterogeneity between studies was quantified using
the I2 statistic.
Sensitivity analyses were conducted by excluding the largest
study and by excluding the studies that did not calculate BMI using
objective measures of height and weight. To assess the potential
effect of reverse causality, in the same studies, we compared data
that were non-left censored with those that were. As the studies
varied by the length of follow-up, maximum periods of left censor-
ing requested (3, 5, or 10 years) differed between studies. We also
compared the associations by study design, by method of dementia
ascertainment, and by study baseline mean age. All statistical
analyses were performed using Stata/SE 14.0 (Stata Corp LP.,
USA).
100× last bodyweight measure prior to dementia followup−baseline bodyweight measureð Þ
baseline body weight measure
 date at last body weight measure−date at baseline bodyweight measureð Þ
365:25
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3 | RESULTS
Results from 23 studies comprised 2 790 753 participants (54%
women) in whom 57 294 cases of all-cause dementia were accumu-
lated during a mean of 9.6 years of disease surveillance. Of these
cases, 6792 were classed as nonvascular dementia, and 1214 were
recorded as vascular dementia. Of the studies included, information
from 14 cohort studies (n = 728 959; 26.1%) were previously
unpublished, and four were from clinical trial populations (n = 23 864;
0.9%). Most studies were from Europe (n = 2 758 444; 98.8%), with
one study9 contributing more than 70% of participants (79% cases of
all-cause dementia). Study characteristics are shown in Tables S1 and
S2. In brief, mean age at baseline ranged from 36 to 83 years in men
and 37 to 84 years in women. Mean duration of follow-up varied from
4 to 38 years, with an overall median of 9 years. Mean BMIs at study
baseline were 21.9 to 28.2 kg/m2 in men and 22.4 to 28.8 kg/m2 in
women; for WC, the corresponding results were 96.9 to 100.7 and
80.7 to 97.5 cm.
F IGURE 1 Association between body mass index (BMI) and incident fatal and nonfatal dementia and its major subtypes. Hazard ratios (HRs)
and 95% confidence intervals (CIs) adjusted for age, smoking, and education or socio-economic status
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A non-linear association between BMI with all-cause dementia
was observed: compared with the referent group (BMI: 18.5-22.4 kg/
m2) those who were underweight had a one-quarter greater risk of
dementia (HR: 1.26, 95% CI, 1.20-1.31; Figure 1). This association
remained similar after excluding the first 3, 5, or 10 years (median 10
years) of follow-up in a subset of studies (1.35 [1.24-1.46]; Figure S2a;
Table S3). Relative to the referent group, individuals with upper-nor-
mal BMI, overweight or obesity had a 10% to 15% lower dementia
risk (Figure 1). Similar results were obtained after adjustment for age
(Figures S3-S6). Additional adjustment for cardiometabolic risk factors
did not materially alter the relationship (model 3; Table S4). Neither
were results significantly different in a range of sensitivity analyses
(Table S5; Figure S7). Further, the associations were comparable
between studies with baseline mean age younger than 60 and 60
years and older (Figure S8) and before and after exclusion of the first
3, 5, or 10 years (median 10 years; Figure S2a; Table S3).
As with all-cause dementia, the association between BMI and
nonvascular dementia risk was non-linear. Relative to lower-normal
BMI, individuals categorized as underweight were at approximately
one-quarter increased dementia risk (1.28 [1.06-1.54]; Figure 1;
Table S4). Adjustment for cardiometabolic risk factors did not
materially affect the association (Table S4). The findings were simi-
larly robust when restricting the analysis to studies that used mea-
sured height and weight. Findings were also consistent between
clinical trials and observational studies and between studies with
baseline mean age younger 60 and 60 years and older (Figures S8
and S9). There was no evidence of a sex difference in the associa-
tion (Figure 2). Relative to the referent group, individuals with
upper-normal BMI, overweight, or obesity had 10% lower dementia
risk (Figure 1). After excluding the first few years of follow-up
(median 7.5 years), the increased risk of nonvascular dementia in
the underweight category remained, but the association was no
longer significant in the overweight and obese categories (Fig-
ure S2b; Table S3).
Both individuals with underweight or obesity were at increased
vascular dementia risk. Compared with the referent group, those who
were underweight had an approximate 80% greater dementia risk,
and for those in the obese category, the risk was approximately 50%
higher (Figure 1). The excess risk among the obese group was largely
mediated by cardiometabolic risk factors (HR for model 3: 1.26 [0.87-
1.84]; Table S4). Sensitivity analyses indicated findings compatible
with the main result (Figure S9). There was no evidence of a sex dif-
ference in the association between BMI and vascular dementia risk
(Figure 2). The association was broadly similar in studies with baseline
mean age younger than 60 and 60 years and older (Figure S8). Exclud-
ing the first few years of follow-up (median 7.5 years) did not materi-
ally influence the relationship (Figure S2c; Table S3).
A non-linear association was observed between WC and all-cause
dementia among the 13 studies (725 522 individuals; 54.5% women;
7057 cases) that contributed to the analysis. Compared with individ-
uals in the lowest fifth of WC, individuals with larger WC had 15% to
22% lower all-cause dementia risk (Figure 3). Similar results were
obtained when adjusted for age or after adjustment for car-
diometabolic risk factors (Figures S10-S13; Table S6). The estimates
tended to be larger for studies that used death records to ascertain
dementia status rather than those that used medical examination
(Figure S14). Data from clinical trials produced similar results to those
from nontrial populations (Figure S15). The estimate of effect was
more pronounced for studies with baseline mean age younger than 60
than 60 years and older especially at higher WC categories
(Figure S16).
Pooling data from ten studies (5319 nonvascular dementia cases)
indicated that, compared with the lowest fifth, all WC categories were
associated with lower nonvascular dementia risk (Figure 3; Table S6).
F IGURE 2 Associations between body mass index (BMI) and incident fatal and nonfatal dementia subtypes by sex. Hazard ratios (HRs) and
95% confidence intervals (CIs) adjusted for age, smoking, and education or socio-economic status
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Adjustment for cardiometabolic risk factors did not alter the
association (Table S6). Data from clinical trials produced a similar
pattern (Figure S15), and there was little evidence of a sex difference
in the association (Figure 4).
For vascular dementia (808 cases), compared with the referent
category, individuals in the highest fifth of WC had roughly one-
quarter higher risk (1.23 [0.97-1.55]) that was attenuated after
further adjustment for cardiometabolic risk factors (Figure 3;
Table S6). No sex difference was evident (Figure 4). Data from clin-
ical trial participants contained too few cases to draw meaningful
conclusions (Figure S15). Only the highest WC category in studies
with baseline mean age 60 years and older was associated with
increased vascular dementia risk (Figure S16).
In the analysis of weight change (111 620 individuals; 44.8%
female; 5626 dementia cases), compared with individuals who
maintained a relatively stable weight during follow-up, individuals
with greater than or equal to 0.5% annual weight loss had approxi-
mately one-third greater all-cause dementia risk (1.32 [1.18-1.47];
Table 2). In contrast, greater than or equal to 0.5% annual weight gain
was not associated with dementia risk (1.00 [0.89-1.12]; Table 2). The
results remained unchanged for models 1 and 3, and when studies
were stratified by baseline mean age (Figures S17-S19; Table 2). For
F IGURE 3 Association
between waist circumference and
incident fatal and nonfatal
dementia and its major subtypes.
Hazard ratios (HRs) and 95%
confidence intervals (CIs)
adjusted for age, smoking, and
education or socio-economic
status
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greater than or equal to 0.5% annual weight loss, the estimate of
effect was more pronounced for studies that ascertained dementia by
medical examination than studies that used death records
(Figure S20).
As with all-cause dementia, greater than or equal to 0.5% annual
weight loss was associated with higher nonvascular dementia risk
(1.41 [1.19-1.67]), whereas greater than or equal to 0.5% annual
weight gain was not associated with risk (0.99 [0.83-1.19]; Table 2).
For vascular dementia, opposing trends were observed: a trend
towards increased risk was observed in those with greater than or
equal to 0.5% annual weight gain (1.21 [0.98-1.49]) but only in those
with baseline mean age younger than 60 years (Figure S19). Weight
F IGURE 4 Associations between waist circumference and incident fatal and nonfatal dementia subtypes by sex. Hazard ratios (HRs) and 95%
confidence intervals (CIs) adjusted for age, smoking, and education or socio-economic status
TABLE 2 Adjusted hazard ratios (HR) with 95% confidence intervals (CI) of dementia by annual percent weight change
Dementia Type ≥0.5% Weight Loss per Year Reference ≥0.5% Weight Gain per Year
All-cause dementia, 15 studies
N (cases) 23 590 (1668) 44 425 (2254) 43 605 (1704)
Model 2a HR (95% CI) 1.32 (1.18-1.47) 1.00 1.00 (0.89-1.12)
I2 (%) 46.2 54.0
Model 3b HR (95% CI) 1.28 (1.15-1.42) 1.00 0.99 (0.89-1.11)
I2 (%) 41.1 48.8
Nonvascular dementia, 10 studies
N (cases) 8106 (898) 10 929 (932) 9926 (652)
Model 2a HR (95% CI) 1.41 (1.19-1.67) 1.00 0.99 (0.83-1.19)
I2 (%) 51.2 51.3
Model 3b HR (95% CI) 1.36 (1.15-1.61) 1.00 0.98 (0.81, 1.17)
I2 (%) 49.0 51.0
Vascular dementia, 7 studies
N (cases) 6000 (151) 9034 (225) 8275 (181)
Model 2a HR (95% CI) 1.11 (0.88-1.39) 1.00 1.21 (0.98-1.49)
I2 (%) 0 0
Model 3b HR (95% CI) 1.09 (0.87-1.36) 1.00 1.13 (0.92-1.40)
I2 (%) 0 0
aHazard ratio adjusted for age, smoking, education/socio-economic status.
bHazard ratios adjusted for age, smoking, education/socio-economic status, diabetes, systolic blood pressure, total cholesterol, blood pressure lowering
medication, cholesterol lowering medication, and glucose lowering medication.
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loss was not associated with increased vascular dementia risk
(Table 2).
4 | DISCUSSION
This is the largest study to characterize the relationship between mea-
sures of body size and weight change with dementia outcomes. We
demonstrated that the relationship between body size, weight change,
and subsequent risk varies by dementia subtype. When considering
all-cause dementia risk, and hence its major subtype of nonvascular
dementia, there was no evidence that excess body weight (measured
by either BMI or WC) conferred higher risk. Rather, levels of BMI
greater than or equal to 22.5 kg/m2 (and higher WCs) were associated
with a slightly lower dementia risk in later life. Conversely, and in
agreement with previous findings,6,7,14 individuals who were catego-
rized as underweight had higher all-cause dementia risk compared
with those with lower-normal BMI. For vascular dementia, only the
highest levels of BMI and WC were associated with increased risk rel-
ative to lower-normal BMI and the lowest fifth of WC.
The main novel finding, however, relates to how weight change
appears to influence dementia risk in later life. Relative to weight
maintenance, weight loss over follow-up was associated with approxi-
mately 30% and 40% increased risk of all-cause dementia and non-
vascular dementia, respectively. The association between weight loss
and nonvascular dementia may reflect the subclinical expression of
prodromal dementia (ie, where an individual has early cognitive
impairment but remains functionally independent), or in epidemiologi-
cal terms, reverse causality. In support of this argument, weight loss
has been observed in the preclinical stage of autosomal dominant
Alzheimer disease, suggesting that decreasing BMI could be a conse-
quence, rather than a risk factor, of dementia.43
An additional, albeit more speculative, explanation may be patho-
physiological such as weight loss–induced cortical thinning, as cere-
bral atrophy is a characteristic of dementia. In a cohort of healthy
elderly individuals, faster cognitive decline and accelerated atrophy
rate were observed in those with relative weight loss greater than or
equal to 5% (equivalent to greater than or equal to 1.2% annual loss)
compared with those with relative weight loss less than 5% (equiva-
lent to less than 1.2% annual loss).44 Similarly, a Norwegian study that
assessed percent change in BMI in midlife reported that while greater
than or equal to 5% loss (equivalent to approximately greater than or
equal to 0.6% annual loss) was associated with increased risk of
dementia-related mortality, a gain of greater than or equal to 20%
(equivalent to approximately greater than or equal to 2.2% annual
gain) was associated with reduced risk.45
Conversely, for vascular dementia, weight gain was associated
with a modest 20% increased risk but only in those aged younger than
60 years at study baseline. This is consistent not only with what we
know about weight gain being a risk factor for other vascular condi-
tions such as coronary heart disease46,47 but also with the diminution
of the strength in the association between vascular risk factors such
as diabetes and blood pressure with vascular risk at older ages.48
Moreover, data from animal studies have indicated that weight gain is
associated with increased vascular dementia risk.49
For all-cause dementia, and its major subtype, that of nonvascular
dementia, there was no evidence that carrying excess body weight
(either in general or more centrally) conferred increased risk. Rather,
individuals with a BMI of greater than or equal to 22.5 kg/m2 (and
higher WCs) had a slightly lower risk of dementia in later life. Con-
versely, and in agreement with some previous findings,6,7,14 individ-
uals who were categorized as underweight had a one-quarter greater
risk of developing all-cause dementia compared with those with
lower-normal BMI. When we attempted to exclude those individuals
who may have had undetected signs of cognitive impairment at study
baseline by excluding the first few years of follow-up, the relationship
remained.
To date, evidence from Mendelian randomization studies has pro-
vided little support of a relationship between low levels of BMI with
future risk of Alzheimer disease, implying that reverse causality or
residual confounding may be driving the observed effect in observa-
tional studies. However, as Mendelian randomization studies do not
use methods that are suited to capturing non-linear associations, the
potential for other explanations, other than reverse causality, to
explain the observed association remains.50
For vascular dementia, the relationship with body size was similar
to other vascular conditions with both underweight and obesity con-
ferring increased risk. Underweight individuals had 75% greater vas-
cular dementia risk, which was unaltered by excluding the first 5 years
of data. Individuals with obesity had 50% greater risk, possibly due to
the adverse effects of high levels of BMI on other vascular risk factors
as the relationship was significantly attenuated after adjustment for
vascular risk factors. An increased vascular dementia risk was
observed for WC but only among those with the highest levels of cen-
tral obesity.
Recent studies have suggested that the association between
BMI and dementia risk is dependent on the age when BMI was
assessed.37,51 We investigated the association separately for midlife
and late life by stratifying studies by their baseline mean age. Aside
from the effect of weight gain on vascular dementia risk, our results
indicated that there was no evidence of any difference between the
two age groups, although the crude dichotomization of age pre-
cludes us from definitely concluding that there is no evidence of an
age effect in the association between body size and dementia risk.
Similarly, this study found no evidence to suggest that the associa-
tions reported herein differed between women and men. In addition
to its large sample size and number of dementia cases, key strengths
of the study included the ability to look at the effect of a measure
of central obesity and the influence of weight change on the associa-
tion between body size and dementia outcomes. BMI and WC were
divided into five categories to allow the study of the relationship
with dementia in more detail. The lowest fifth of WC was chosen as
referent as four studies already included women with abdominal
obesity in this group. Nevertheless, using the second or third fifth as
referent would not have changed the relationship between WC and
dementia. Limitations included the between-study differences in
LEE ET AL. 11 of 14
design and methodologies used in the ascertainment of dementia as
well as different lengths of study follow-up. In regard to the latter,
we attempted to address the potential for reverse causality by
excluding the first 3, 5, or 10 years of follow-up (depending on the
data set). However, given the often long lag period between prodro-
mal dementia until dementia onset, this may not have been a suffi-
ciently long enough period of time to fully exclude the potential for
reverse causality. Previous reports have indicated that it is necessary
to exclude up to 20 years of follow-up in order to fully negate the
effects of inadvertently including individuals with early cognitive
impairment at study baseline.11 In our analysis of weight change, we
were unable to distinguish between intentional (eg, because of a
diagnosis of hypertension or diabetes in midlife) versus unintentional
weight loss (ie, because of pre-existing disease), which may have
diluted the observed associations. Studies that contributed to the
weight change analysis also varied in the length of time between
first and last weight measurement. We standardized weight change
across studies by calculating annual percent weight change; how-
ever, this method assumes a consistent weight change over time,
which may not be valid. In addition, we attempted to distinguish
between vascular dementia and nonvascular dementia separately,
but the dichotomization is problematic as the two subtypes fre-
quently co-occur.52 Finally, as body size (both underweight and over-
weight) is related to a wide range of chronic illnesses, and dementia
is mainly a disease of aging, individuals may have died before they
had the opportunity to develop dementia. We were unable to apply
competing risks methodology in the current analysis, which may
have resulted in an underestimation of the relationship between
body size and dementia risk. It potentially could also explain why
above normal levels of BMI and WC were not associated with
increased all-cause dementia risk.
Excess body weight was not associated with risk of all-cause
dementia and its major subtype of nonvascular dementia, whereas it
was positively associated with risk of vascular dementia. Under-
weight was related to increased risk of all-cause dementia and both
its subtypes, possibly due to reverse causality. Weight loss in midlife
to late life was associated with an increased risk of developing
dementia and nonvascular dementia. Future studies should focus on
examining the basis between weight loss and increased nonvascular
dementia risk to determine if it has a pathophysiological basis or is
due to limitations in the epidemiology. Given the known adverse
effects of excess body weight on a wide range of health outcomes,
from a public health perspective, maintaining a healthy body weight
and minimizing weight fluctuation in adult life should continue to be
widely promoted.
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